Wakefulness-promoting agents effective for excessive daytime sleepiness but patients may discontinue due to side effects

A systematic review and analysis of 14 trials found that solriamfetol, armodafinil–modafinil, and pitolisant reduce excessive daytime sleepiness (ESA) for patients with obstructive sleep apnea (OSA) already using conventional therapy. However, patients may be more likely to discontinue the use of these medications due to adverse events including headache, anxiety, and insomnia. The review is published in Annals of Internal Medicine.